ZEJULA Is the Only Once-Daily Oral PARP Inhibitor1-3

Description of Treatment

ZEJULA is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2, which play a role in DNA repair1.

ZEJULA has high bioavailability and extensive tissue distribution, as well as a long half-life1,3

Highly bioavailable - Absolute bioavailability of ~73%, indicating minimal first-pass effect

Highly bioavailable1

Absolute bioavailability of ~73%, indicating minimal first-pass effect

Concentrates in tissue - Extensive tissue distribution, with a Vd/F of 1,220 L

Concentrates in tissue1

Extensive tissue distribution, with a Vd/F of 1,220 L

Long half-life - Mean half-life of 36 h, allowing for once-daily dosing

Long half-life1

Mean half-life of 36 h, allowing for once-daily dosing

 

Watch Video

Please see Important Safety Information below and full Prescribing Information.

View trial design and results

References: 1. ZEJULA [package insert]. Waltham, MA: TESARO, Inc.;2017. 2. Rubraca [package insert]. Boulder, CO: Clovis Oncology, Inc.; 2016. 3. Lynparza [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.